Donate
09 Nov 2016

YposKesi, the 1st French industrial pharmaceutical company for producing gene and cell therapy drugs for rare diseases

Illustration for article: YposKesi, the 1st French industrial pharmaceutical company for producing gene and cell therapy drugs for rare diseases
AFM-Téléthon and the SPI fund, managed by Bpifrance under the Programme d’Investissement d’Avenir, are creating YposKesi, the first French industrial pharmaceutical company dedicated to producing gene and cell therapy drugs for rare diseases.
AFM-Téléthon and the 'Sociétés de Projets Industriels' SPI [Industrial Projects Companies] investment fund, managed by Bpifrance under the Programme d’Investissement d’Avenir (PIA), are creating YposKesi, the first French company to develop and produce gene and cell therapy products. This new company aims to make the first treatments available to patients and market them at a fair and controlled price, consistent with the commitment made by AFM-Téléthon and its founders' characteristic general interest strategy. By relying on proofs of concept of innovative therapies created by leading French research in this field, this new benchmark company is taking up the challenge of industrialising innovative treatment methods for rare diseases, but also for common diseases. It is the founding element for a first-class translational sector, generating high added-value and major economic benefits for France.
 
Located in Evry (Essonne), this industrial platform, effective since 2nd November 2016, is made up of more than 100 experts in bioproduction and has a first production building covering 5,000 m2 (formerly Généthon Bioprod). It is aiming at European leadership and, with this objective, by 2021 will bring together nearly 300 engineers, pharmacists, technicians and experts in three production buildings totalling 13,000 m2. It will meet the needs of AFM-Téléthon laboratories (Généthon and CECS/I-Stem), as well as those of academic and industrial biotechnology organisations, for clinical trials or post-MA (Marketing Authorisation) distribution. The first therapeutic batches produced by this platform are gene therapy batches for muscle, blood and immune system diseases.
 
AFM-Téléthon has a majority-holding in YposKesi, which is also governed by Bpifrance through the 'Sociétés de Projets Industriels' SPI [Industrial Projects Companies] investment fund, managed on behalf of the French government. AFM-Téléthon contributes expertise developed by its Généthon and CECS/I-stem laboratories, as well as existing production capacity, and will invest 37.5 million euros between now and 2022. The SPI fund will invest a total of 84 million euros as part of the Programme d’Investissement d’Avenir.
 
For AFM-Téléthon, the creation of this new pharmaceutical company is an essential step to achieve its objective, which has never changed: TO CURE.
 
"As an association of patients and parents of patients, our mission is not to perform scientific exploits but to cure rare diseases that have long been considered as incurable. This new pharmaceutical company, created with the French public investment bank, is part of the general interest strategy that we have always followed. It is a facility that should enable us to convert scientific advances into effective medicines and to keep the promise we have made to our children. We are proud to take up this major challenge and we are determined to realise our objective of a fair and controlled price to benefit patients and the whole community," declared Laurence Tiennot-Herment, President of AFM-Téléthon.
 
Magali Joëssel, Director the SPI fund, states "creating YposKesi is the beginning of a great adventure, making it possible to consolidate the leading French and European company in the sector. This investment will also make it possible to support the entire ecosystem, start-ups and industrial companies, by offering to produce their therapies, in the largest manufacturing centre for gene and cell therapies in Europe. This project meets all our objectives: to support new industries, creating jobs and structure for the sector, with a partner that shares our values."